PT1218494E - Composicoes e metodos para inibir a paragem do ciclo celular g2 e para sensibilizar celulas perante agentes que danificam o adn - Google Patents

Composicoes e metodos para inibir a paragem do ciclo celular g2 e para sensibilizar celulas perante agentes que danificam o adn

Info

Publication number
PT1218494E
PT1218494E PT00964563T PT00964563T PT1218494E PT 1218494 E PT1218494 E PT 1218494E PT 00964563 T PT00964563 T PT 00964563T PT 00964563 T PT00964563 T PT 00964563T PT 1218494 E PT1218494 E PT 1218494E
Authority
PT
Portugal
Prior art keywords
methods
compositions
inhibiting
cell cycle
stop
Prior art date
Application number
PT00964563T
Other languages
English (en)
Inventor
Masashi Suganuma
Takumi Kawabe
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP26939899A external-priority patent/JP2001086991A/ja
Priority claimed from JP34032299A external-priority patent/JP2001157585A/ja
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Publication of PT1218494E publication Critical patent/PT1218494E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
PT00964563T 1999-09-22 2000-09-21 Composicoes e metodos para inibir a paragem do ciclo celular g2 e para sensibilizar celulas perante agentes que danificam o adn PT1218494E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26939899A JP2001086991A (ja) 1999-09-22 1999-09-22 オリゴペプチド
JP34032299A JP2001157585A (ja) 1999-11-30 1999-11-30 抗癌療法の増強剤とそのスクリーニング方法

Publications (1)

Publication Number Publication Date
PT1218494E true PT1218494E (pt) 2005-08-31

Family

ID=26548750

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00964563T PT1218494E (pt) 1999-09-22 2000-09-21 Composicoes e metodos para inibir a paragem do ciclo celular g2 e para sensibilizar celulas perante agentes que danificam o adn

Country Status (11)

Country Link
US (2) US6881575B1 (pt)
EP (1) EP1218494B1 (pt)
JP (1) JP4610828B2 (pt)
AT (1) ATE292677T1 (pt)
AU (1) AU7548500A (pt)
CA (1) CA2385257A1 (pt)
DE (1) DE60019318T2 (pt)
DK (1) DK1218494T3 (pt)
ES (1) ES2239037T3 (pt)
PT (1) PT1218494E (pt)
WO (1) WO2001021771A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1295540C (zh) * 2001-12-17 2007-01-17 奥林巴斯株式会社 显微镜系统
PT1483290E (pt) 2002-01-17 2008-09-19 Takeda Pharmaceutical Peptídeos e peptidomiméticos possuindo actividade antiproliferativa e/ou que aumentam os agentes ou tratamentos de danificação dos ácidos nucleicos
JP4532116B2 (ja) 2002-01-18 2010-08-25 ノボザイムズ エー／エス アラニン２，３−アミノムターゼ
ES2369534T3 (es) 2002-06-06 2011-12-01 Canbas Co. Ltd. Compuestos que anulan el punto de control g2 del ciclo celular inducido por daños en el adn y/o que incrementan la actividad anticancerosa de los tratamientos que dañan el adn.
EA009337B1 (ru) 2003-01-09 2007-12-28 Пфайзер Инк. Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
CA2522562C (en) 2003-04-17 2013-09-03 Janssen Pharmaceutica N.V. 2-phenyl-benzimidazol and 2-phenyl-imidazo-`4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer
WO2004106924A2 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab Testing cell cycle regulation effect of a compound using a hollow fibre cell implant
US7479484B2 (en) 2003-06-25 2009-01-20 Takeda Pharmaceutical Company Limited Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity
US7358046B2 (en) * 2003-08-08 2008-04-15 Canbas Co., Ltd. Sensitivity test to predict efficacy of anti-cancer therapies
MXPA06002296A (es) 2003-08-29 2006-05-22 Pfizer Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
JP2007519609A (ja) * 2003-09-17 2007-07-19 アイコス コーポレイション 細胞増殖を制御するためのｃｈｋ１インヒビターの使用
EP1824832B1 (en) 2004-06-30 2011-04-27 Janssen Pharmaceutica NV Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
US8084454B2 (en) 2007-04-11 2011-12-27 Canbas Co., Ltd. Compounds with anti-cancer activity
CN101678002A (zh) 2007-05-08 2010-03-24 先灵公司 使用含有替莫唑胺的静脉注射用配制剂的治疗方法
TW201000116A (en) * 2008-05-14 2010-01-01 Takeda Pharmaceutical Peptide compound and use thereof
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
EA038338B1 (ru) * 2016-02-23 2021-08-11 Такеда Фармасьютикал Компани Лимитед Ингибиторы взаимодействий -аррестина с рецептором нейрокинина 1 для лечения боли
CN110904070A (zh) * 2019-12-05 2020-03-24 王连生 一种促进心肌再生的重组人chk1蛋白激酶水凝胶及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443962A (en) * 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
AU6014998A (en) * 1997-01-13 1998-08-03 Pharmacia & Upjohn Company Special catalytic domains of cdc25c phosphatase

Also Published As

Publication number Publication date
JP2003518368A (ja) 2003-06-10
ATE292677T1 (de) 2005-04-15
WO2001021771A2 (en) 2001-03-29
CA2385257A1 (en) 2001-03-29
EP1218494B1 (en) 2005-04-06
AU7548500A (en) 2001-04-24
DK1218494T3 (da) 2005-08-08
JP4610828B2 (ja) 2011-01-12
US7851592B2 (en) 2010-12-14
US20050059116A1 (en) 2005-03-17
DE60019318D1 (de) 2005-05-12
US6881575B1 (en) 2005-04-19
WO2001021771A3 (en) 2002-02-14
DE60019318T2 (de) 2006-03-09
ES2239037T3 (es) 2005-09-16
EP1218494A2 (en) 2002-07-03

Similar Documents

Publication Publication Date Title
PT1218494E (pt) Composicoes e metodos para inibir a paragem do ciclo celular g2 e para sensibilizar celulas perante agentes que danificam o adn
NL301145I2 (nl) Tirbanibulin
NO20033858D0 (no) Aryl- og heteroarylurea-CHK1-inhibitorer for anvendelse som radiosensitiviseringsmidler og chamosensitiviseringsmidler
IS6816A (is) Aðferðir til að meðhöndla p38 kínasa tengda sjúkdóma og pýrrólótríazín sambönd, sem gagnleg eru semkínasa hindrar
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
NO20014303L (no) JAK-3-inhibitorer for behandling av allergiske lidelser
NO20061194L (no) Mitotiske kinesininbibitorer
WO2005030121A3 (en) Compounds, compositions and methods
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
BR0309556A (pt) Inibidores de metaloproteinase pirimidina-2,4,6-triona
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
ATE408412T1 (de) Verwendung von cannabidiol zur hemmung von gehirntumorzellmigration
NO20054082L (no) Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
NO20005448D0 (no) Indolderivater og deres anvendelse for behandling av maligne og andre sykdommer som er basert pÕ patologisk celleproliferering
YU49101A (sh) Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
EA200800374A1 (ru) 1,4-дигидропиридин-конденсированные гетероциклы, способы их получения, применение и содержащие их композиции
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
DE60023660D1 (de) Antizymmodulatoren sowie deren verwendung
ATE403433T1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen